OneVentures Welcome Image

Investment with Purpose

OneVentures builds great businesses working alongside driven and ambitious management teams, contributing venture capital and strong operational and executional team skills. The companies and the individuals we back are commercialising products and services that tackle large global market needs and seeking to accelerate their international growth and development.

OneVentures invests Australia wide and is based in Sydney with offices in Melbourne and Brisbane. Our companies operate in global markets with offices in San Francisco, Palo Alto, New Jersey, Boston, Los Angeles, Manilla, Ho Chi Minh City and London.

The firm has $320M in funds under management across 3 funds and 8 co-investment funds. Fund II and III are open for applications from technology and healthcare businesses.

A global growth investment focus drives investment selection and fund creation. OneVentures portfolio includes companies with truly disruptive and innovative products tackling multi-$Billion problems from healthcare: needle free vaccine delivery, dementia patient care and allergy treatment; though to the connected world: HR management in the cloud, personalised learning and virtual communications.

Proudly supporting

Heads Over Heels
Investor Portal Log In

Connect With Us

About OneVentures

Established as an early stage investment business in 2007, the firm moved into venture capital in late 2008 and launched the only VC fund in Australia in 2010 post the global financial crisis.

The team has a stellar track record in building high growth companies in international markets. A unique blend of entrepreneurs, technology business founders and business executives combined with software, applied sciences and medical domain depth.  We apply this expertise to mentor and collaborate with Founders, CEOs and company management and provide  leadership on the boards of our investee companies. 

Our investors work with us to support our companies by providing strategic advice and access to networks. They trust us to deliver results and provide a high level of accountability and transparency.  We have an extensive investor network of high net worth investors and family offices representing approximately $20B in net worth. Exit value created for investors delivered by members of the investment team is approximately $1.5B including 4 Nasdaq companies.

We focus on bringing innovative products to global markets and hold ourselves and our companies to high standards of performance. We ensure our companies are adequately capitalised to allow management to achieve significant commercial milestones and ultimately deliver financial returns to the business owners and our investors.

We partner with some of the largest and best known global investors and corporations.



OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Partner

Dr Paul Kelly

Dr Paul Kelly
Managing Partner 

Anne-Marie Birkill

Anne-Marie Birkill
Managing Partner 

Graeme Wald

Graeme Wald

Dr Amir Zalcenstein

Dr Amir Zalcenstein
Investment Manager

Sarah Meibusch

Sarah Meibusch
Investment Manager

James McGrath

James McGrath
Investment Associate

Sakura Holloway

Sakura Holloway
Investment Analyst

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob

Jen Ball

Jen Ball
Office Manager

Sanice Embleton

Sanice Embleton
Administration Assistant

Board of Directors

Walter Lewin

Walter Lewin
OneVentures Board of Directors

Simon Moore

Simon Moore
OneVentures Board of Directors

Roger Massy-Greene

Roger Massy-Greene
OneVentures Board of Directors


OneVentures has three funds, two of which are actively investing. The OneVentures Innovation and Growth Fund II and OneVentures Healthcare Fund III, have approximately $200M in available capital and are currently seeking investment opportunities in technology and healthcare businesses.

All three of our main funds are Early Stage Venture Capital Limited Partnerships (ESVCLPs) providing investors tax benefits for their VC asset class investing. We also raise additional capital alongside our funds from our limited partners as our investments mature, providing companies with the potential for larger rounds of financing and co-investment opportunities. This allow investors to improve their returns and back their favoured companies further. Recent larger raises have included rounds of up to $30M.

OneVentures is currently looking for truly transformative companies to join its portfolio of innovative companies. If you think your company has what it takes, read the Application for Funding page and submit your application now.


OneVentures Healthcare Fund III

OneVentures recently launched its $170M Healthcare Fund III, which is focused on investing in therapeutics, devices or diagnostics at or near clinical development with a clear commercial, regulatory and reimbursement pathway; and well defined value inflection and exit points on deal entry. The OneVentures' team has deep experience in driving opportunities through the FDA regulatory process and commercialising biomedical innovations in global markets. 

The fund launched in December 2016 and is licenced under the Commonwealth government’s Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an $85 million license supported by matching capital from its private investor network. The government funding provides benefits to investors both during the investment phase and on realisation. 

The fund will invest $10 to $20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics.

Innovation and Growth Fund Fund II

The OneVentures Innovation and Growth Fund II was launched in October 2014 with $100M in available funds for technology and healthcare businesses. 

The fund is focused on later stage companies seeking growth and development capital for offshore expansion and market growth. Fund II is screening currently for technology companies with a strong product market fit and a clear path to revenue of $3 to 5M over the next 12 months. In particular, we are looking at investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success. The fund looks to invest on average $3 to 5M into any one company although rounds of up to $10M+ are also possible.

OneVentures Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund established to provide capital and expertise into early stage (seed and Series A companies). This fund was launched in 2010 with the Commonwealth Government committing $20M from its Innovation Investment Fund programme. Capital from this fund is fully deployed.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

Latest News

  • Citadel Group aquires OneVentures portfolio company Charm Health

    by OneVentures Administrator | Sep 04, 2017

    OneVentures is delighted to announce that The Citadel Group Limited (ASX: CGL) has entered into a definitive agreement to acquire its OneVentures Innovation Fund portfolio company Charm Health International Pty Ltd as part of expanding its e-health offering.

    Headquartered in Brisbane, Charm Health ( is Australia’s leading supplier of specialist oncology e-health systems, with its solutions used by leading public and private health providers of cancer care.  Its flagship software, CHARM™, provides:

    • comprehensive multi-site functionality that manages all clinical and administrative aspects of a patient’s cancer care,
    • a single oncology electronic medical record, with real-time access to patient information by every member of the care team shared across multiple locations,
    • enhanced clinical and prescriptive decision support,
    • solutions to critical inefficiencies in cancer care, such as complex medication management and multi-disciplinary resource coordination.

    Anne-Marie Birkill, Managing Partner at OneVentures and chair of the board  at Charm Health said: “While Charm Health has been courted by a number of suitors thanks in part to the global reach of Charm Health’s advisors InterFinancial, we are pleased that the company will become part of the Australian-based Citadel Group. With an emerging reputation as a leader in e-health, Citadel has the skills and resources to support the continued expansion of Charm Health’s customer base both locally and internationally. Being part of the innovative Citadel Group also provides exciting opportunities for the talented Charm Health team and the promise of continued commitment to excellence in client service that has become a Charm Health hallmark.”

    OneVentures first invested in Charm Health in 2013, through OneVentures Innovation Fund I, and has been instrumental in supporting the Charm Health team in increasing market share and reinforcing the company’s reputation for delivering Australia’s  best of breed medical oncology software solution.

    Gary Lakin, Chief Executive Officer of Charm Health said; “Being a OneVentures portfolio company has enabled Charm Health to grow to be the leading Australian oncology e-health solution.  We are excited to become part of Citadel to drive the business through its next growth phase and to accelerate innovation that will result in the highest return on investment for our clients and improved outcomes for the patients they serve.”

    Consideration for the acquisition comprises an upfront payment of $8.2million. This represents an acquisition multiple of approximately six times FY17 pro forma EBITDA. Additional payments will be made for agreed over-performance, staggered over the two years following completion.

    Both the Citadel Group and Charm Health Board of Directors have unanimously approved the acquisition. It is subject to customary conditions precedent, and is expected to complete by mid-September 2017.

    Charm Health was supported in this transaction by the awesome folk at InterFinancial Corporate Finance (Hyun-ju Johnson and Sharon Doyle) and DLA Piper (Joel Cox and Dylan Burke).  


    For more information, contact:

    Anne-Marie Birkill

    Tel: +61 0419 789401


    About OneVentures

    OneVentures is an Australian venture capital firm with $320M under management. OneVentures utilises its strengths in business building to accelerate portfolio company performance. A global growth focus drives investment selection with portfolio companies addressing multi-billion dollar problems from breakthroughs in healthcare (e.g. needle free vaccine delivery) through to the transformation of online education (e.g. next generation courseware and personalised learning) and the connected world (IoT, SaaS and virtual reality).

    Launched in 2010, OneVentures Innovation Fund I is a $40 million venture capital fund formed as an Early Stage Venture Capital Limited Partnership. OneVentures Fund I is supported by the Australian Government through the Industry Innovation Fund (IIF) program with this funding matched by institutional investors, individual high net worth investors and family offices. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.

    Read more about OneVentures at

    About Charm Health

    Charm Health is Australia’s leading supplier of specialist oncology e-health system. Its flagship product CHARM™ manages the clinical and administrative coordination of all aspects of a patient’s cancer care across multiple locations. Used by the foremost providers of cancer care, it is currently deployed at 100 private and public hospital sites in Australia. In the past decade over 70,000 patients have had their treatment managed via the CHARM™ platform.

    Read more about Charm Health at

    About the Citadel Group

    Citadel specialises in managing information management in complex environments through integrating know-how, systems and people to provide information on an anywhere-anytime basis. We are a leader in the development and delivery of managed service solutions to government and the private sector.

    The majority of Citadel Group’s revenues are derived from long term managed services, and software-as-a-service solutions.

    For further information please visit                

Full story

Contact Us

For Entrepreneurs

We are now screening companies for OneVentures Fund II which is a Series A and beyond growth fund focusing on the technology sector. To qualify for funding, your company should meet the following criteria:

  • Australian domiciled company
  • We invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security
  • If a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process
  • If from another sector, your company should be generating sustainable revenue and have a strong market validation
  • Approaching profitability with capital required to fuel growth and global expansion

If you meet the above criteria, send us a brief document (a 2-page executive summary or introductory PowerPoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to

  • Summarize in 2 sentences what your company does (this is important)
  • Identify the market, value proposition and your competitive advantage
  • Tell us about your progress to date
  • State your revenue for the last financial year and projected revenue for current financial year
  • Indicate capital required and how it will be used
  • Include 3 point bios of each executive and contact details

We will review your proposal and endeavour to revert to you within 2 weeks. 


For Investors

Investor enquiries:


General Enquiries

General enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Level 13
179 Elizabeth Street
Sydney NSW 2000


The Precinct
Level 2, 315 Brunswick St
Fortitude Valley QLD 4006



C/o FB Rice
Level 14, 90 Collins Street
Melbourne VIC 3000